tradingkey.logo

Uplizna Significantly Improves Generalized Myasthenia Gravis Symptoms In Acetylcholine Receptor Autoantibody-Positive Patients Over 52 Weeks

ReutersMar 13, 2025 2:52 PM

- Amgen Inc AMGN.O:

  • UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS

  • AMGEN INC: NO NEW SAFETY SIGNALS WERE IDENTIFIED FROM STUDY

  • AMGEN: UPLIZNA REGULATORY FILING ACTIVITIES UNDERWAY, SUBMISSION TO BE COMPLETE IN H1 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI